Skip to main content
NCBI home page
British Medical Journal logoLink to British Medical Journal
. 1971 Nov 13;4(5784):391–394. doi: 10.1136/bmj.4.5784.391

Effect of Hormonal Therapy on Plasma Testosterone Levels in Prostatic Carcinoma

M R G Robinson, B S Thomas
PMCID: PMC1799485  PMID: 5124437

Abstract

Plasma concentrations of testosterone were estimated in normal men, in patients before treatment for prostatic cancer, and in patients who had had various forms of endocrine treatment for prostatic carcinoma. There was no decline in plasma testosterone levels with age. Patients with non-metastatic disease had levels similar to those of normal controls, but in advanced metastatic disease the levels were low. After orchidectomy the plasma testosterone level fell to that found in normal women. In every patient stilboestrol in doses as small as 1 mg three times a day suppressed plasma testosterone at first to negligible amounts, irrespective of the clinical response. Subsequently a small but significant rise in the concentration was always observed over a period of six months' oestrogen therapy. Pituitary ablation with yttrium-90 lowered the plasma testosterone concentration again to negligible amounts in patients who had been on stilboestrol. In advanced metastatic disease this was often associated with relief of pain. Preliminary studies with aminoglutethimide indicate that it can produce biochemical and clinical effects similar to those of pituitary ablation.

Full text

PDF
391

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alder A., Burger H., Davis J., Dulmanis A., Hudson B., Sarfaty G., Straffon W. Carcinoma of prostate: response of plasma luteinizing hormone and testosterone to oestrogen therapy. Br Med J. 1968 Jan 6;1(5583):28–30. doi: 10.1136/bmj.1.5583.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BULBROOK R. D., FRANKS L. M., GREENWOOD F. C. Hormone excretion in prostatic cancer: the early and late effects of endocrine treatment on urinary oestrogens, 17-ketosteroids and 17-ketogenic steroids. Acta Endocrinol (Copenh) 1959 Aug;31:481–499. [PubMed] [Google Scholar]
  3. Belitsky P., Elhilali M. M., Oliver J. A. Effect of stilbestrol on the isoenzymes of lactate dehydrogenase in benign and malignant prostatic tissue. J Urol. 1970 Sep;104(3):453–456. doi: 10.1016/s0022-5347(17)61757-9. [DOI] [PubMed] [Google Scholar]
  4. FERGUSSON J. D., PHILLIPS D. E. A clinical evaluation of radioactive pituitary implantation in the treatment of advanced carcinoma of the prostate. Br J Urol. 1962 Dec;34:485–492. doi: 10.1111/j.1464-410x.1962.tb06535.x. [DOI] [PubMed] [Google Scholar]
  5. Farnsworth W. E. A direct effect of estrogens on prostatic metabolism of testosterone. Invest Urol. 1969 Jan;6(4):423–427. [PubMed] [Google Scholar]
  6. Forchielli E., Rao G. S., Sarda I. R., Gibree N. B., Pochi P. E., Strauss J. S., Dorfman R. I. Effect of ethinyloestradiol on plasma testosterone levels and urinary testosterone excretion in man. Acta Endocrinol (Copenh) 1965 Sep;50(1):51–54. doi: 10.1530/acta.0.0500051. [DOI] [PubMed] [Google Scholar]
  7. GOODWIN D. A., RASMUSSEN-TAXDAL D. S., FERREIRA A. A., SCOTT W. W. Estrogen inhibition of androgen-maintained prostatic secretion in the hypophysectomized dog. J Urol. 1961 Jul;86:134–136. doi: 10.1016/S0022-5347(17)65124-3. [DOI] [PubMed] [Google Scholar]
  8. Gaunt R., Steinetz B. G., Chart J. J. Pharmacologic alteration of steroid hormone functions. Clin Pharmacol Ther. 1968 Sep-Oct;9(5):657–681. doi: 10.1002/cpt196895657. [DOI] [PubMed] [Google Scholar]
  9. Hughss S. W., Burley D. M. Aminoglutethimide: a "side-effect" turned to therapeutic advantage. Postgrad Med J. 1970 Jul;46(537):409–416. doi: 10.1136/pgmj.46.537.409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. KELLY K. H., FELDSTED E. T., BROWN R. F., ORTEGA P., BIERMAN H. R., LOWBEER B. V. A., SHIMKIN M. B. Irradiation of the normal human hypophysis in malignancy: report of three c cases receiving 8,100-10,000 r tissue dose to the pituitary gland. J Natl Cancer Inst. 1951 Apr;11(5):967–983. [PubMed] [Google Scholar]
  11. Kato T., Horton R. Studies of testosterone binding globulin. J Clin Endocrinol Metab. 1968 Aug;28(8):1160–1168. doi: 10.1210/jcem-28-8-1160. [DOI] [PubMed] [Google Scholar]
  12. Southren A. L., Gordon G. G., Tochimoto S. Further study of factors affecting the metabolic clearance rate of testosterone in man. J Clin Endocrinol Metab. 1968 Aug;28(8):1105–1112. doi: 10.1210/jcem-28-8-1105. [DOI] [PubMed] [Google Scholar]
  13. Thomas B. S. Measurement of plasma testosterone as the iodomethyldimethylsilyl ether by gas-liquid chromatography. J Chromatogr. 1971 Mar 24;56(1):37–50. doi: 10.1016/s0021-9673(00)97775-6. [DOI] [PubMed] [Google Scholar]
  14. Williams J. P., Still B. M., Pugh R. C. The diagnosis of prostatic cancer: cytological and biochemical studies using the franzen biopsy needle. Br J Urol. 1967 Oct;39(5):549–554. doi: 10.1111/j.1464-410x.1967.tb11793.x. [DOI] [PubMed] [Google Scholar]
  15. Young H. H., 2nd, Kent J. R. Plasma testosterone levels in patients with prostatic carcinoma before and after treatment. J Urol. 1968 Jun;99(6):788–792. doi: 10.1016/S0022-5347(17)62795-2. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES